Skip to main content
OpenTrials

Clinical trial condition

Lymphoma, Non-Hodgkin

Explore clinical trials studying Lymphoma, Non-Hodgkin. Study availability and eligibility vary by location and protocol.

2,774 public trials 698 recruiting studies
Refine in advanced search Browse all conditions

Lymphoma, Non-Hodgkin trial results

Active, Not Recruiting

Vorinostat and Azacitidine in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer or Nasal Natural Killer T-Cell Lymphoma

NCT00336063

Conditions
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Lymphoma, Lymphoma, Extranodal NK-T-Cell, +8 more
Locations
  • Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore, Maryland, United States
  • Chinese University of Hong Kong-Prince of Wales Hospital Shatin, Hong Kong
  • National Cancer Center Hospital Tokyo, Japan
  • National University Hospital Singapore Singapore
View Trial Details
Active, Not Recruiting

Edwards EVOQUE Eos MISCEND Study

NCT02718001

Conditions
Cardiovascular Diseases, Deglutition Disorders, Digestive System Diseases, +22 more
Locations
  • Sutter Mills-Peninsula Burlingame, California, United States
  • Cedars-Sinai Medical Center Los Angeles, California, United States
  • Kaiser Permanente San Francisco San Francisco, California, United States
  • Emory University Hospital/Emory University Hospital Midtown Atlanta, Georgia, United States
View all 19 locations
View Trial Details
Active, Not Recruiting

Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma

NCT04450173

Conditions
Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage III Follicular Lymphoma, Ann Arbor Stage IV Follicular Lymphoma, +13 more
Locations
  • University of California, San Francisco (UCSF) Fresno Fresno, California, United States
  • University of California, Los Angeles Los Angeles, California, United States
  • University of California Davis Comprehensive Cancer Center Sacramento, California, United States
  • University of California, San Diego San Diego, California, United States
View Trial Details
Active, Not Recruiting

A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

NCT06508658

Conditions
Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations
  • City of Hope National Medical Center /ID# 273338 Duarte, California, United States
  • Valkyrie Clinical Trials /ID# 269935 Los Angeles, California, United States
  • Desert Regional Medical Center /ID# 272437 Palm Springs, California, United States
  • Lutheran Medical Center- Cancer Centers of Colorado /ID# 265823 Golden, Colorado, United States
View all 176 locations
View Trial Details
Active, Not Recruiting

MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas

NCT03697512

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +11 more
Locations
  • CHU UCL Namur / site Godinne Yvoir, Belgium
  • CHU de Tours - Hôpital Bretonneau Tours, Cedex 01, France
  • CHU de Montpellier Montpellier, Cedex 05, France
  • CHU d'Estaing Clermont-Ferrand, Cedex 1, France
View all 36 locations
View Trial Details
Active, Not Recruiting

A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)

NCT04404660

Conditions
Burkitt Lymphoma, DNA Virus Infections, Disease Attributes, +19 more
Locations
  • City of Hope National Medical Center Duarte, California, United States
  • University of California San Diego Health (UCSD) La Jolla, California, United States
  • University of California Davis (UC Davis) Sacramento, California, United States
  • University of California San Francisco (UCSF) San Francisco, California, United States
View all 34 locations
View Trial Details
Active, Not Recruiting

Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP

NCT05798156

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations
  • Uniklinik Innsbruck Innsbruck, Austria
  • Kepler Universitätsklinikum Linz, Austria
  • Ordensklinikum Linz - Barmherzige Schwestern Linz, Austria
  • Ordensklinikum Linz - Elisabethinen Linz, Austria
View all 28 locations
View Trial Details

Related conditions